Protalix provides business update; PRX-115 Phase 2 IND effective, gout market focus

Protalix BioTherapeutics, Inc.

PRX-115 Phase 1 data show rapid, durable urate lowering lasting 12 weeks at higher doses; Phase 2 IND effective.
Fabry drug Elfabrio launched through Chiesi; CHMP negative opinion on E4W dosing under appeal, outcome Q1 2026.
Fabry market projected $3.4B by 2030; Elfabrio target capture 15-20% share.
Elelyso revenue continues via Pfizer and Fiocruz partnerships.
New renal pipeline includes PRX-119 (long-acting DNase I) and Secarna RNA collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.